effective immunomodulation with pomalidomide during induction tst for aml and mds
Published 5 years ago • 88 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
6:11
immunomodulation with pomalidomide in aml and high-risk mds
-
4:05
elotuzumab, pomalidomide, and dexamethasone for advanced myeloma
-
2:58
immunomodulatory drug combinations for multiple myeloma
-
1:06
long-term outcomes of the ocean study: melflufen is superior to pomalidomide in r/r myeloma
-
1:56
randomized trials of pomalidomide combinations for mm
-
3:32
potential applications of artificial intelligence in myeloma
-
4:36
what is isatuximab? and how does it compare with daratumumab?
-
4:51
the current frontline treatment strategy in multiple myeloma
-
10:44
isatuximab plus pomalidomide/low-dose dex vs pomalidomide/low-dose dex in pts with rrmm (icaria-mm)
-
6:50
an overview of the immunotherapy landscape in aml: antibodies, bispecifics, & car-t
-
5:18
immunomodulation for improving long-term outcomes in myeloma
-
2:00
the role of pomalidomide-dexamethasone in patients with multiple myeloma
-
1:08
novel immunotherapies for multiple myeloma & other exciting developments
-
1:57
the safety and efficacy of iberdomide for the treatment of multiple myeloma
-
1:45
isatuximab and pomalidomide for the treatment of mm
-
1:09
an update on alliance a061202: addition of ixazomib to pomalidomide-dexamethasone in r/r myeloma
-
1:08
the impact of extramedullary multiple myeloma on outcomes with ide-cel
-
1:11
advances that have been made in the molecular characterization of multiple myeloma
-
1:48
a phase ii study of daratumumab and pomalidomide in previously treated patients with al amyloidosis
-
1:50
safety & efficacy of isatuximab, pomalidomide and dexamethasone in frail patients with r/r myeloma
-
3:06
how immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma
-
2:42
enhancing outcomes in multiple myeloma with immune-based strategies